<?xml version="1.0" encoding="UTF-8"?>
<p id="Par57">The anti-tumor effects of SGN-35 are evaluated only in patients with measurable lesions according to the Revised Response Criteria for Malignant Lymphoma [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
